DrugPatentWatch Database Preview
VYVANSE Drug Profile
When do Vyvanse patents expire, and when can generic versions of Vyvanse launch?
This drug has one hundred and forty-seven patent family members in twenty-six countries.
The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. Three suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
Summary for VYVANSE
| International Patents: | 147 |
| US Patents: | 18 |
| Applicants: | 2 |
| NDAs: | 2 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 14 |
| Clinical Trials: | 54 |
| Patent Applications: | 79 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | VYVANSE at DailyMed |
Pharmacology for VYVANSE
| Drug Class | Central Nervous System Stimulant |
| Physiological Effect | Central Nervous System Stimulation |
Medical Subject Heading (MeSH) Categories for VYVANSE
Synonyms for VYVANSE
| (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenyl-ethyl]hexanamide; methanesulfonic acid |
| (2S)-2,6-DIAMINO-N-[(1S)-1-METHYL-2-PHENYLETHYL]HEXANAMIDE DIMETHANESULFONATE |
| 137L333 |
| 608137-33-3 |
| AKOS030254940 |
| AN-27750 |
| BIS(METHANESULFONIC ACID); VYVANSE |
| CETWSOHVEGTIBR-FORAGAHYSA-N |
| CHEMBL1201178 |
| CTK5B2291 |
| D04747 |
| DTXSID60209653 |
| Elvanse (TN) |
| L-Lysine-d-amphetamine dimesylate |
| lis-dexamfetamine dimesylate |
| Lisdexamfetamine dimesylate |
| Lisdexamfetamine dimesylate (USAN) |
| Lisdexamfetamine dimesylate [USAN] |
| Lisdexamfetamine dimesylate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material |
| Lisdexamfetamine mesilate |
| Lisdexamfetamine mesilate (JAN) |
| Lisdexamfetamine mesylate |
| LS-186600 |
| Lys-Amp |
| Lys-d-Amp |
| NRP 104 |
| NRP-104 |
| OR074086 |
| SCHEMBL678421 |
| SJT761GEGS |
| SPD 489 |
| SPD-489 |
| SPD489 |
| UNII-SJT761GEGS |
| Venvanse |
| Vyvanse (TN) |
US Patents and Regulatory Information for VYVANSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire Development | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-005 | Dec 10, 2007 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Shire Dev Llc | VYVANSE | lisdexamfetamine dimesylate | TABLET, CHEWABLE;ORAL | 208510-005 | Jan 28, 2017 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Shire Development | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-006 | Dec 10, 2007 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Shire Dev Llc | VYVANSE | lisdexamfetamine dimesylate | TABLET, CHEWABLE;ORAL | 208510-006 | Jan 28, 2017 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for VYVANSE
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg | ➤ Subscribe | 2011-02-23 |
Non-Orange Book US Patents for VYVANSE
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,060,708 | Active agent delivery systems and methods for protecting and administering active agents | ➤ Try a Free Trial |
| 7,163,918 | Iodothyronine compositions | ➤ Try a Free Trial |
| 7,169,752 | Compounds and compositions for prevention of overdose of oxycodone | ➤ Try a Free Trial |
| 6,716,452 | Active agent delivery systems and methods for protecting and administering active agents | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for VYVANSE
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2005032474 | ➤ Try a Free Trial |
| Mexico | PA06003619 | ➤ Try a Free Trial |
| Australia | 2001298033 | ➤ Try a Free Trial |
| Canada | 2420590 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for VYVANSE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2013 00043 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: LISDEXAMFETAMIN, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER ET MESYLAT SALT; NAT. REG. NO/DATE: MT499080, MT499081, MT499082 20130214; FIRST REG. NO/DATE: PL PL 08081/0050-0052 20130201 |
| 90058-4 | Sweden | ➤ Try a Free Trial | PRODUCT NAME: LISDEXAMFETAMIN VALFRITT I FORMEN AV ETT FARMACEUTISKT GODTAGBART SALT, SAERSKILT ETT MESYLATSALT; NAT. REG. NO/DATE: 47382 20130722; FIRST REG.: GB PL 08081/0050-52 20130201 |
| 13/038 | Ireland | ➤ Try a Free Trial | PRODUCT NAME: LISDEXAMFETAMINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY A MESYLATE SALT; NAT REGISTRATION NO/DATE: PA0689/006/001 PA0689/006/002 |
| /2016 | Austria | ➤ Try a Free Trial | PRODUCT NAME: LISDEXAMFETAMIN, OPTIONAL IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON, INSBESONDERE EINES MESILAT-SALZES; NAT. REGISTRATION NO/DATE: 136851-136853 20160412; FIRST REGISTRATION: PL08081/0050-PL08081/0052 20130201 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
